Detalles de la búsqueda
1.
Sensitizing protective tumor microenvironments to antibody-mediated therapy.
Cell
; 156(3): 590-602, 2014 Jan 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-24485462
2.
Entirely noninvasive outcome prediction in central nervous system lymphomas using circulating tumor DNA.
Blood
; 143(6): 522-534, 2024 Feb 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-37946299
3.
Reassessing the Chronic Lymphocytic Leukemia International Prognostic Index in the era of targeted therapies.
Blood
; 2024 Apr 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-38620092
4.
Multicenter development of a PET-based risk assessment tool for product-specific outcome prediction in large B-cell lymphoma patients undergoing CAR T-cell therapy.
Eur J Nucl Med Mol Imaging
; 51(5): 1361-1370, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38114616
5.
Long-term remission in a patient with relapsed Richter's transformation treated with CD19-directed chimeric antigen-receptor T-cells after allogeneic stem cell transplantation.
Eur J Haematol
; 112(6): 984-987, 2024 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-38316549
6.
Fludarabine, cyclophosphamide, and rituximab as first-line treatment in patients with chronic lymphocytic leukemia: A long-term analysis of the German CLL Study Group (GCLLSG) registry.
Eur J Haematol
; 2024 May 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-38693677
7.
Management of front line chronic lymphocytic leukemia.
Am J Hematol
; 97 Suppl 2: S3-S10, 2022 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-36125035
8.
Health-related quality of life with fixed-duration venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: Results from the randomized, phase 3 CLL14 trial.
Am J Hematol
; 96(9): 1112-1119, 2021 09 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34050972
9.
Specialized palliative care in patients with haematological malignancies receiving chimeric antigen receptor T-cell therapy.
Br J Haematol
; 2024 Mar 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-38522848
10.
Mode of progression after first line treatment correlates with outcome of chronic lymphocytic leukemia (CLL).
Am J Hematol
; 94(9): 1002-1006, 2019 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-31222797
11.
CLL-IPI: valid in the era of oral inhibitors?
Blood
; 138(2): 106-107, 2021 07 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-34264275
12.
Economic evaluation of chronic lymphocytic leukemia from a hospital management perspective.
Eur J Haematol
; 98(2): 169-176, 2017 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-27727474
13.
Outcome Prediction in Patients With Large B-cell Lymphoma Undergoing Chimeric Antigen Receptor T-cell Therapy.
Hemasphere
; 7(1): e817, 2023 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-36698613
14.
Potential synergy between radiotherapy and CAR T-cells - a multicentric analysis of the role of radiotherapy in the combination of CAR T cell therapy.
Radiother Oncol
; 183: 109580, 2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-36842663
15.
CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial.
Nat Med
; 29(11): 2844-2853, 2023 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-37872225
16.
Salvage High-dose Melphalan With Autologous Stem cell Transplantation as Bridge to Consolidation Therapy for Chemoresistant Aggressive B-cell Lymphoma.
Clin Lymphoma Myeloma Leuk
; 22(7): e498-e506, 2022 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35094950
17.
miRNA deregulation by epigenetic silencing disrupts suppression of the oncogene PLAG1 in chronic lymphocytic leukemia.
Blood
; 114(15): 3255-64, 2009 Oct 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-19692702
18.
Overexpression of TOSO in CLL is triggered by B-cell receptor signaling and associated with progressive disease.
Blood
; 112(10): 4213-9, 2008 Nov 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-18708628
19.
Long Term Follow-up Data and Health-Related Quality of Life in Frontline Therapy of Fit Patients Treated With FCR Versus BR (CLL10 Trial of the GCLLSG).
Hemasphere
; 4(1): e336, 2020 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-32072150
20.
Efficacy and safety of obinutuzumab combined with fludarabine and cyclophosphamide (FCG) or bendamustine (BG) in relapsed or refractory CLL patients followed by maintenance therapy with obinutuzumab for responding patients.
Leuk Lymphoma
; 64(2): 478-482, 2023 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-36423347